Overview:

Optic nerve glioma (ONG), also known as optic pathway glioma, is a rare type of brain tumor that affects the optic nerve. The optic nerve is responsible for transmitting visual information from the eye to the brain, so an ONG can cause vision loss and other symptoms.

The Optic Nerve Glioma Market Report is expected to reach USD 619.7 Million by 2030 at 6.5% CAGR during the forecast period 2022-2030. The market may register strong growth in the coming years as new and effective treatments are making grounds. Growing awareness among patients regarding such diseases is expected to increase the expansion scope for the global optic nerve glioma market. 

However, treatment for this disease includes radiation therapy, which can affect the brain and it also incurs high cost. Market Research Future (MRFR) believes that these factors could emerge as market deterrents in the coming years.

Segmentation:

The global study on the optic nerve glioma market trends includes a detailed understanding of segments like types, diagnosis, treatment and end users. This will help provide data and a closer look at various aspects that can influence the market outcome later. 

By types, the review of the optic nerve glioma market includes segments like malignant optic nerve glioma and benign optic nerve glioma.

By diagnosis, the report on the optic nerve glioma market studied segments like a neurological exam, Magnetic Resonance Imaging (MRI), Computed Tomography (CT), biopsy, and others. The MRI segment is getting traction for its ability to provide a comprehensive analysis of symptoms.

By treatment, the report on the optic nerve glioma market includes segments like surgery, chemotherapy, radiation therapy, and others. 

By end users, the report on the optic nerve glioma market includes segments like diagnostic centers, pharmacy hospitals and clinics, and others. 

Regional Analysis:

Better infrastructure, expenditure capacity, research scope, and integration of advanced technologies are expected to boost the American optic nerve glioma market. This region displays the potential to lead the market and introduce changes in the coming years. Asia Pacific would record growth as its massive population would back the treatment procedure. 

Competitive Landscape:

Sigma-Aldrich Co., Thermo Fisher Scientific Inc., Emcure Pharmaceuticals ltd., Taj Pharmaceuticals Limited, Pfizer Inc., Teva Pharmaceutical Industries Ltd, Novartis International AG, Philips Healthcare, GE Healthcare, Siemens Healthcare, Toshiba Medical Systems Corporation, Shimadzu Corporation, and others are companies with the ability to impact the global output significantly. This depends mostly on the strategic developments made by these companies to boost their own market stand.

Industry News:

In May 2020, a new study by the researchers from the Washington School of Medicine in St. Louis revealed that children with the genetic condition neurofibromatosis type 1 (NF1) are showing chances of developing brain and nerve tumors. In fact, this tumor has the potential to turn the child suffering from such symptoms blind. However, new findings, published in the May 1 issue of Nature Communications, revealed that a new way of treatment could slow down the growth of this cancerous cell in mice and researchers believe that this treatment can be effective for low-grade brain tumors in people with NF1.

In April 2020, the US Food and Drug Administration approved the use of selumetinib for children of 2 years of age and older with neurofibromatosis type 1 (NF1) as the studies revealed positive signs for the phase 2 trial in the March 18 issue of the New England Journal of Medicine. The medicine is expected to be effective for the treatment of diseases like optic pathway glioma. 

However, the recent COVID-19 pandemic could impact the global market for optic nerve glioma to some extent as the countermeasures for the pandemic have imposed some restraints in providing facilities to treat such diseases.

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street, 5Th Floor,

New York, New York 10013

United States of America

+1 628 258 0071

Email: sales@marketresearchfuture.com